GE's SPECT System Has FDA Clearance, Offers More Affordable Nuclear Medicine Solution
GE Healthcare announced the Brivo NM615 was cleared by the U.S. Food and Drug Administration (FDA) in January 2012. An advanced single-head nuclear medicine gamma camera with Single Photon Emission Computation Tomography (SPECT) capability, the system gives doctors the ability to lower injected patient dose by as much as 50 percent of those of standard nuclear medicine scanning protocols, or the potential for patients to spend less time on the table during exams, without compromising image quality. Made possible through GE’s detector design and evolution technology, this single-head system has the ability to achieve shortened scan times rivaling a dual-head system.
GE Healthcare Brivo NM615 is engineered to help accommodate more patients than earlier GE nuclear medicine systems. With its 28 inch (70cm) wide bore and table capable of handling patients up to 500lbs. (227 kilograms), the Brivo NM615 provides access to a wide variety of patient sizes. The system can also be upgraded on site to the GE Healthcare Discovery NM630 or the Discovery NM/CT 670 SPECT/CT hybrid systems through on-site hardware changes. As a result, Brivo NM615 may protect the initial investment by expanding the ability to serve patients well into the future at faster speeds and with SPECT/CT hybrid scanning capability.
The Elite NXT detector enables exceptional image quality and is designed to offer outstanding SPECT resolution and exceptional contrast for impressive image quality. Ultra-thin design and auto-body contouring minimize the distance between the patient and the detectors for excellent resolution while SPECT-optimized collimators and the exceptionally high count rate enable extremely precise event detection.
In institutions and centers with high patient volumes, Brivo NM615 may provide an affordable solution to help clinicians increase capacity without compromising image quality; and due to the simple upgrade path, physicians facing budget constraints can choose the solution that meets their needs.
Shorter acquisition times and dose reduction capabilities are possible with the Brivo NM615 system only when used in combination with the relevant features offered on the Xeleris 3 processing and review workstation.
Brivo NM615 can be used with the advanced Xeleris workstation - which integrates new and existing nuclear medicine equipment, including GE and non-GE devices, and is designed to provide consistent results and enhanced workflow. Xeleris can keep clinicians connected to images and applications from PACS and PCs within their institution and remotely.
For more information: www.gehealthcare.com